AR096758A1 - Inhibidores cristalinos de bromodominios - Google Patents

Inhibidores cristalinos de bromodominios

Info

Publication number
AR096758A1
AR096758A1 ARP140102431A ARP140102431A AR096758A1 AR 096758 A1 AR096758 A1 AR 096758A1 AR P140102431 A ARP140102431 A AR P140102431A AR P140102431 A ARP140102431 A AR P140102431A AR 096758 A1 AR096758 A1 AR 096758A1
Authority
AR
Argentina
Prior art keywords
bromodominium
ethanesulfonamide
difluorophenoxy
pyrrole
dihydro
Prior art date
Application number
ARP140102431A
Other languages
English (en)
Inventor
Gong Yuchuan
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of AR096758A1 publication Critical patent/AR096758A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

N-[4-(2,4-difluorofenoxi)-3-(6-metil-7-oxo-6,7-dihidro-1H-pirrol[2,3-c]piridin-4-il)fenil]etansulfonamida y formas cristalinas de la misma como ingrediente farmacéutico adecuado para composiciones farmacéuticas de utilidad en el tratamiento de enfermedades, por ejemplo, cáncer. Reivindicación 2: Una forma cristalina aislada de N-[4-(2,4-difluorofenoxi)-3-(6-metil-7-oxo-6,7-dihidro-1H-pirrol[2,3-c]piridin-4-il)fenil]etansulfonamida, caracterizada porque la forma cristalina tiene un patrón de difracción de rayos X en polvo que comprende los siguientes valores pico 2q ± 0,2: 6,2º, 9,0º, 11,0º, 12,3º, 12,6º, 13,1º, 14,1º, 15,6º, 16,4º, 16,5º, 16,9º, 17,8º, 18,1º, 18,3º, 18,9º, 20,4º, 21,1º, 21,6º, 21,8º, 22,1º, 22,9º, 23,2º, 24,4º, 24,7º, 25,6º, 26,3º, 27,0º y 27,3º.
ARP140102431A 2013-06-28 2014-06-26 Inhibidores cristalinos de bromodominios AR096758A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361840777P 2013-06-28 2013-06-28

Publications (1)

Publication Number Publication Date
AR096758A1 true AR096758A1 (es) 2016-02-03

Family

ID=51261220

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140102431A AR096758A1 (es) 2013-06-28 2014-06-26 Inhibidores cristalinos de bromodominios

Country Status (33)

Country Link
US (3) US9321765B2 (es)
EP (1) EP3013826B1 (es)
JP (1) JP6423425B2 (es)
KR (1) KR102323829B1 (es)
CN (1) CN105473586B (es)
AR (1) AR096758A1 (es)
AU (2) AU2014302252B2 (es)
BR (1) BR112015032736A2 (es)
CA (1) CA2916221C (es)
CL (1) CL2015003722A1 (es)
CR (1) CR20160036A (es)
CY (1) CY1119066T1 (es)
DK (1) DK3013826T3 (es)
DO (1) DOP2015000304A (es)
ES (1) ES2636939T3 (es)
HK (2) HK1223354A1 (es)
HR (1) HRP20171154T1 (es)
IL (1) IL243202B (es)
LT (1) LT3013826T (es)
ME (1) ME02801B (es)
MX (1) MX360065B (es)
NZ (1) NZ631112A (es)
PE (1) PE20160287A1 (es)
PH (1) PH12015502792A1 (es)
PL (1) PL3013826T3 (es)
PT (1) PT3013826T (es)
RS (1) RS56318B1 (es)
RU (1) RU2675268C2 (es)
SG (1) SG11201510692TA (es)
SI (1) SI3013826T1 (es)
TW (1) TWI639594B (es)
UY (1) UY35632A (es)
WO (1) WO2014210425A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016507496A (ja) 2012-12-21 2016-03-10 ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｃｏｒｐ． ブロモドメイン阻害剤としての新規複素環式化合物
NZ712453A (en) 2013-03-15 2020-06-26 Incyte Holdings Corp Tricyclic heterocycles as bet protein inhibitors
CA2915561C (en) 2013-06-21 2020-09-22 Zenith Epigenetics Corp. Novel substituted bicyclic compounds as bromodomain inhibitors
DK3010503T3 (da) 2013-06-21 2020-05-25 Zenith Epigenetics Ltd Hidtil ukendte bicykliske bromodomæne-inhibitorer
CA2917319A1 (en) 2013-07-08 2015-01-15 Incyte Holdings Corporation Tricyclic heterocycles as bet protein inhibitors
JP6542212B2 (ja) 2013-07-31 2019-07-10 ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． ブロモドメイン阻害剤としての新規キナゾリノン
EP3290407B1 (en) 2013-10-18 2020-01-01 Celgene Quanticel Research, Inc Bromodomain inhibitors
WO2015081203A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
US9315501B2 (en) 2013-11-26 2016-04-19 Incyte Corporation Bicyclic heterocycles as BET protein inhibitors
US9309246B2 (en) 2013-12-19 2016-04-12 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
EA034972B1 (ru) 2014-04-23 2020-04-13 Инсайт Корпорейшн 1h-пирроло[2,3-c]пиридин-7(6h)-оны в качестве ингибиторов белков bet
JP6599979B2 (ja) 2014-09-15 2019-10-30 インサイト・コーポレイション Ｂｅｔタンパク質阻害剤として用いるための三環式複素環化合物
CA2966298A1 (en) 2014-12-01 2016-06-09 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
WO2016087942A1 (en) 2014-12-01 2016-06-09 Zenith Epigenetics Corp. Substituted pyridines as bromodomain inhibitors
US10292968B2 (en) 2014-12-11 2019-05-21 Zenith Epigenetics Ltd. Substituted heterocycles as bromodomain inhibitors
EP3233846A4 (en) 2014-12-17 2018-07-18 Zenith Epigenetics Ltd. Inhibitors of bromodomains
US20180200261A1 (en) * 2015-07-20 2018-07-19 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
AR106520A1 (es) 2015-10-29 2018-01-24 Incyte Corp Forma sólida amorfa de un inhibidor de proteína bet
MD3442972T2 (ro) 2016-04-15 2020-08-31 Abbvie Inc Inhibitori ai bromodomeniului
KR20240033293A (ko) * 2016-06-20 2024-03-12 인사이트 코포레이션 Bet 저해제의 결정질 고체 형태
WO2018106988A1 (en) * 2016-12-09 2018-06-14 Smet Pharmaceutical Inc. Biologically active compositions containing two different classes of chemical compounds for treating solid tumors
CN109384784B (zh) * 2017-08-10 2021-01-12 浙江海正药业股份有限公司 磺酰胺类衍生物、其制备方法及其在医药上的用途
AU2019268333A1 (en) 2018-05-15 2020-10-29 Abbvie Inc. Treating solid tumors with bromodomain inhibitors
US11633399B2 (en) 2018-12-25 2023-04-25 Sol-Gel Technologies Ltd. Treatment of skin disorders with compositions comprising an EGFR inhibitor
WO2020232214A1 (en) * 2019-05-14 2020-11-19 Abbvie Inc. Treating acute myeloid leukemia (aml) with mivebresib, a bromodomain inhibitor
JP2023501584A (ja) * 2019-11-13 2023-01-18 ラプト・セラピューティクス・インコーポレイテッド Ｃ－ｃケモカイン受容体４型アンタゴニストの結晶形態、およびその使用
CN110964691B (zh) * 2019-12-31 2020-10-30 深圳新赛尔生物科技有限公司 子宫内膜干细胞的定向成脂分化培养
EP4092027A4 (en) * 2020-01-19 2024-02-14 Chia Tai Tianqing Pharmaceutical Group Co Ltd CRYSTAL FORM AND SALT FORM OF A BROMODOMAIN PROTEIN INHIBITOR AND METHOD FOR THE PRODUCTION THEREOF
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
US11746932B2 (en) 2020-07-02 2023-09-05 Hempvana, Llc Expandable and retractable hose reinforced with hemp
US11583602B2 (en) 2021-06-23 2023-02-21 Kimtron, Inc. System and method for ultra-close proximity irradiation of rotating biomass

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6271380B1 (en) * 1998-12-30 2001-08-07 Dupont Pharmaceuticals Company 1H-imidazo[4,5-d]pyridazin-7-ones, 3H-imidazo-[4,5-c]pyridin-4-ones and corresponding thiones as corticotropin releasing factor (CRF) receptor ligands
BR0311697A (pt) * 2002-06-06 2005-03-22 Eisai Co Ltd Novos derivados condensados de imidazol
AR045595A1 (es) * 2003-09-04 2005-11-02 Vertex Pharma Composiciones utiles como inhibidores de proteinas quinasas
ES2446647T3 (es) * 2009-11-05 2014-03-10 Glaxosmithkline Llc Inhibidor de bromodominio de benzodiazepina
GB0919434D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
CN104311562B (zh) * 2010-05-14 2017-07-04 达那-法伯癌症研究所 用于治疗瘤形成、炎性疾病和其他失调的组合物和方法
JP5913292B2 (ja) * 2010-05-14 2016-04-27 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 代謝を調節する組成物および方法
AT510136B1 (de) * 2010-07-12 2016-11-15 Primetals Technologies Austria GmbH Verfahren zur herstellung von kohlepartikeln enthaltenden presslingen
WO2013097052A1 (en) * 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors

Also Published As

Publication number Publication date
KR102323829B1 (ko) 2021-11-09
PL3013826T3 (pl) 2017-10-31
CN105473586A (zh) 2016-04-06
HRP20171154T1 (hr) 2017-10-20
RU2016102591A3 (es) 2018-04-25
CR20160036A (es) 2016-05-17
HK1224298A1 (zh) 2017-08-18
PE20160287A1 (es) 2016-05-22
ME02801B (me) 2018-01-20
CA2916221C (en) 2022-08-30
CY1119066T1 (el) 2018-01-10
CN105473586B (zh) 2019-11-05
AU2014302252B2 (en) 2018-03-22
US9321765B2 (en) 2016-04-26
EP3013826A1 (en) 2016-05-04
KR20160025021A (ko) 2016-03-07
SG11201510692TA (en) 2016-01-28
TW201534608A (zh) 2015-09-16
RU2016102591A (ru) 2017-08-03
AU2018201986A1 (en) 2018-04-12
DK3013826T3 (en) 2017-08-28
TWI639594B (zh) 2018-11-01
HK1223354A1 (zh) 2017-07-28
BR112015032736A2 (pt) 2017-07-25
CL2015003722A1 (es) 2016-07-29
US20170066765A1 (en) 2017-03-09
JP6423425B2 (ja) 2018-11-14
NZ631112A (en) 2018-03-23
MX360065B (es) 2018-10-22
MX2015017435A (es) 2016-08-12
RU2675268C2 (ru) 2018-12-18
JP2016525090A (ja) 2016-08-22
WO2014210425A1 (en) 2014-12-31
PT3013826T (pt) 2017-08-11
UY35632A (es) 2015-01-30
LT3013826T (lt) 2017-08-10
PH12015502792A1 (en) 2016-03-21
RS56318B1 (sr) 2017-12-29
ES2636939T3 (es) 2017-10-10
US20150005340A1 (en) 2015-01-01
IL243202A0 (en) 2016-02-29
IL243202B (en) 2019-07-31
DOP2015000304A (es) 2016-02-29
SI3013826T1 (sl) 2017-10-30
AU2014302252A1 (en) 2015-12-24
CA2916221A1 (en) 2014-12-31
EP3013826B1 (en) 2017-05-10
US20160237085A1 (en) 2016-08-18

Similar Documents

Publication Publication Date Title
AR096758A1 (es) Inhibidores cristalinos de bromodominios
MY192084A (en) Pyrazolo-heteroaryl derivative, preparation method and medical use thereof
CL2014001103A1 (es) Compuestos derivados de heteroaril piridona y aza-piridona sustituidas, inhibidores de btk quinasa; composicion farmaceutica que los comprende; proceso de preparacion de la composicion farmaceutica; kit farmaceutico; y uso para el tratamiento de trastornos inmunes, cancer, inflamacion, trastornos neurologicos, entre otros.
CR20190204A (es) Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f] isoquinolina útiles en el tratamiento del cáncer
TN2017000511A1 (en) New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them.
CA2983481A1 (en) Janus kinase inhibitor
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
CL2016000117A1 (es) Autotaxina inhibidores comprende un anillo heteroaromático-bencilamina ciclo basico
TN2017000524A1 (en) New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them
TR201901312T4 (tr) Mcl-1 proteinini inhibe eden tetrahidronaftalen türevleri.
MY192521A (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
EA201890820A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ДВОЙСТВЕННЫХ ИНГИБИТОРОВ DYRK1/CLK1
BR112016015838A8 (pt) compostos heterocíclicos aromáticos, composição farmacêutica compreendendo os referidos compostos e produto de combinação
SG11201900868XA (en) Ido1 inhibitor and preparation method and application thereof
MX2020001719A (es) Inhibidores macrocíclicos de mcl-1 y metodos de uso.
MX2020001717A (es) Inhibidores macrociclicos de mcl-1 y metodos de uso.
CL2017003107A1 (es) Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak
SA519402103B1 (ar) 1,6-naphthyridine مشتقات 1، 6 نفثيرايدين CDK4/6 على شكل مثبط
TW201613864A (en) Novel compounds
GEP20207108B (en) Substituted 2,4 diamino-quinoline as new anticancer agents
WO2014153495A9 (en) Novel stat3 inhibitors
GEP20186876B (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
CU20160140A7 (es) CROMENE Y 1,1 A,2,7B- tetrahidrociclopropa[C]CROMENE PIRIDOPIRAZINEDIONES COMO MODULADORES DE GAMMA-SECRETASA
UY35746A (es) Derivados de fenilalanina sustituidos
CR20160527A (es) Derivados de carboxamida

Legal Events

Date Code Title Description
FB Suspension of granting procedure